SIGA Technologies Inc., is developing products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents. SIGA’s lead product is a smallpox drug that has shown very positive results to date in animal efficacy and human safety studies. SIGA’s product development programs emphasize the increasingly serious problem of emerging pathogens. SIGA has been successful in leveraging its product development platform through partnerships with the National Institutes of Health (NIH) and TransTech Pharma. SIGA has also been successful in obtaining significant funding from the NIH and the Department of Defense.